Incidence of hand-foot syndrome with capecitabine in combination with chemotherapy as first-line treatment in patients with advanced and/or metastatic gastric cancer suitable for treatment with a fluoropyrimidine-based regimen. Clin Transl

metabolite N-desethylsunitinib in sweat of a patient. J Anal Toxicol 2011; 35: 558–565. 65. Lacouture ME, Reilly LM, Gerami P, Guitart J. Hand foot skin reaction in cancer patients treated with the multikinase inhibitors sorafenib and sunitinib. Ann Oncol 2008; 19: 1955–1961. 66. Lee WJ, Lee JL, Chang SE et al. Cutaneous adverse effects in patients treated with the multitargeted kinase inhibitors sorafenib and sunitinib. Br J Dermatol 2009; 161: 1045–1051. 67. Grothey A, Sobrero AF, Siena S et al. Time profile of adverse events (AEs) from regorafenib (REG) treatment for metastatic colorectal cancer (mCRC) in the phase III CORRECT study. J Clin Oncol 2013; 31(Suppl): abstr 3637. 68. Gomez-Martin C, Sanchez A, Irigoyen A et al. Incidence of hand-foot syndrome with capecitabine in combination with chemotherapy as first-line treatment in patients with advanced and/or metastatic gastric cancer suitable for treatment with a fluoropyrimidine-based regimen. Clin Transl Oncol 2012; 14: 689–697. 69. Gressett SM, Stanford BL, Hardwicke F. Management of hand-foot syndrome induced by capecitabine. J Oncol Pharm Pract 2006; 12: 131–141. 70. Rosen AC, Case EC, Dusza SW et al. Impact of dermatologic adverse events on quality of life in 283 cancer patients: a questionnaire study in a dermatology referral clinic. Am J Clin Dermatol 2013; 14: 327–333. 71. McLellan B, Kerr H. Cutaneous toxicities of the multikinase inhibitors sorafenib and sunitinib. Dermatol Ther 2011; 24: 396–400. 72. Charles C, Sultan S, Bungener C et al. Impact of cutaneous toxicities associated with targeted therapies on quality of life. Results of a longitudinal exploratory study [article in French]. Bull Cancer 2013; 100: 213–222. 73. Nardone B, Hensley JR, Kulik L et al. The effect of hand-foot skin reaction associated with the multikinase inhibitors sorafenib and sunitinib on health-related quality of life. J Drugs Dermatol 2012; 11: e61–e65. 74. Haley AC, Calahan C, Gandhi M et al. Skin care management in cancer patients: an evaluation of quality of life and tolerability. Support Care Cancer 2011; 19: 545–554. 75. Dreno B, Bensadoun RJ, Humbert P et al. Algorithm for dermocosmetic use in the management of cutaneous side-effects associated with targeted therapy in oncology. J Eur Acad Dermatol Venereol 2013; 27: 1071–1080. 76. Borovicka JH, Calahan C, Gandhi M et al. Economic burden of dermatologic adverse events induced by molecularly targeted cancer agents. Arch Dermatol 2011; 147: 1403–1409. 77. Dranitsaris G, Vincent MD, Yu J et al. Development and validation of a prediction index for hand-foot skin reaction in cancer patients receiving sorafenib. Ann Oncol 2012; 23: 2103–2108. 78. Tsuchiya N, Narita S, Inoue T et al. Risk factors for sorafenib-induced high-grade skin rash in Japanese patients with advanced renal cell carcinoma. Anticancer Drugs 2013; 24: 310–314. 79. Chren MM, Lasek RJ, Sahay AP, Sands LP. Measurement properties of Skindex16: a brief quality-of-life measure for patients with skin diseases. J Cutan Med Surg 2001; 5: 105–110. 80. Lewis V, Finlay AY. 10 years experience of the Dermatology Life Quality Index (DLQI). J Investig Dermatol Symp Proc 2004; 9: 169–180. 81. Sibaud V, Dalenc F, Chevreau C et al. HFS-14, a specific quality of life scale developed for patients suffering from hand-foot syndrome. Oncologist 2011; 16: 1469–1478. 82. DeSimone PA. Nightly dosing of regorafenib. J Clin Oncol 2015; 33(Suppl): abstr 549. 83. Tabchi S, Ghosn M. Regorafenib: start low and go slow. Target Oncol 2015; 10(3): 445–447. 84. National Cancer Institute. Common Terminology Criteria for Adverse Events (CTCAE) Version 4.0. http://evs.nci.nih.gov/ftp1/CTCAE/About.html (20 April 2015, date last accessed).